Phencyclidine decreases tickling-induced 50-kHz ultrasound vocalizations in juvenile rats: A putative model of the negative symptoms of schizophrenia

Behavioural Pharmacology

Volumn 24, Issue 7, 2013, Pages 543-551

  Boulay, Denis ^a   Ho Van, Sophie ^a   Bergis, Olivier ^a   Avenet, Patrick ^a   Griebel, Guy ^a  

^a SANOFI   (France)

Author keywords

Animal model; Negative symptoms; Phencyclidine; Rat; Schizophrenia; Tickling; Ultrasonic vocalization

Indexed keywords

ARIPIPRAZOLE; BUSPIRONE; DIAZEPAM; EPLIVANSERIN; FLUOXETINE; PHENCYCLIDINE; PSYCHEDELIC AGENT; SS 103800; SSR 103800; SSR 181507; SSR181507; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; EXPERIMENTAL TEST; MALE; NEGATIVE SYNDROME; NONHUMAN; RAT; SCHIZOPHRENIA; SENSORY STIMULATION; TICKLING; ULTRASOUND VOCALIZATION; VOCALIZATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; ULTRASOUND;

ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HALLUCINOGENS; MALE; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; SCHIZOPHRENIA; ULTRASONICS; VOCALIZATION, ANIMAL;

EID: 84888289894     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283654044     Document Type: Article

References (62)

1. Adler CM, Malhotra AK, Elman I, Goldberg T, Egan M, Pickar D, Breier A (1999). Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. Am J Psychiatry 156:1646-1649.
2. Andreasen NC (1990). Positive and negative symptoms: historical and conceptual aspects. Mod Probl Pharmacopsychiatry 24:1-42.
3. Aquila R, Weiden PJ, Emanuel M (1999). Compliance and the rehabilitation alliance. J Clin Psychiatry 60 (Suppl 19):23-27.
4. Ault DT, Werling LL (1999). Phencyclidine and dizocilpine modulate dopamine release from rat nucleus accumbens via sigma receptors. Eur J Pharmacol 386:145-153.
5. Bialy M, Rydz M, Kaczmarek L (2000). Precontact 50-kHz vocalizations in male rats during acquisition of sexual experience. Behav Neurosci 114: 983-990.
6. Black MD, Varty GB, Arad M, Barak S, De LA, Boulay D, et al. (2009). Procognitive and antipsychotic efficacy of glycine transport 1 inhibitors (GlyT1) in acute and neurodevelopmental models of schizophrenia: latent inhibition studies in the rat. Psychopharmacology (Berl) 202:385-396.
7. Bobes J, Arango C, Garcia-Garcia M, Rejas J (2010). Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study. J Clin Psychiatry 71:280-286.
8. Boulay D, Depoortere R, Louis C, Perrault G, Griebel G, Soubrie P (2004). SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: Improvement of social interaction deficits induced by phencyclidine in rats. Neuropharmacology 46:1121-1129.
9. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, et al. (2008). Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol Biochem Behav 91:47-58.
10. Boulay D, Bergis O, Avenet P, Griebel G (2010). The glycine transporter-1 inhibitor SSR103800 displays a selective and specific antipsychotic-like profile in normal and transgenic mice. Neuropsychopharmacology 35:416-427.
11. Boulay D, Lacave M, Bergis O, Avenet P, Griebel G. Bruins Slot LA, Kleven MS, Newman-Tancredi A (2005). Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology 49:996-1006.
12. Burgdorf J, Panksepp J (2001). Tickling induces reward in adolescent rats. Physiol Behav 72:167-173.
13. Burgdorf J, Panksepp J (2006). The neurobiology of positive emotions. Neurosci Biobehav Rev 30:173-187.
14. Burgdorf J, Knutson B, Panksepp J, Shippenberg TS (2001). Evaluation of rat ultrasonic vocalizations as predictors of the conditioned aversive effects of drugs. Psychopharmacology (Berl) 155:35-42.
15. Burgdorf J, Panksepp J, Brudzynski SM, Kroes R, Moskal JR (2005). Breeding for 50-kHz positive affective vocalization in rats. Behav Genet 35:67-72.
16. Burgdorf J, Kroes RA, Moskal JR, Pfaus JG, Brudzynski SM, Panksepp J (2008). Ultrasonic vocalizations of rats (Rattus norvegicus) during mating, play, and aggression: behavioral concomitants, relationship to reward, and self-administration of playback. J Comp Psychol 122:357-367.
17. Burgdorf J, Panksepp J, Moskal JR (2011). Frequency-modulated 50 kHz ultrasonic vocalizations: A tool for uncovering the molecular substrates of positive affect. Neurosci Biobehav Rev 35:1831-1836.
18. Carboni E, Imperato A, Perezzani L, Di CG (1989). Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 28:653-661.
19. Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R, et al. (2003). SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: neurochemical and electrophysiological profile. Neuropsychopharmacology 28:2064-2076.
20. Covington MA, Riedel WJ, Brown C, He C, Morris E,Weinstein S, et al. (2007). Does ketamine mimic aspects of schizophrenic speech J Psychopharmacol 21:338-346.
21. Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Francon D, et al. (2003). SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: behavioral profile predictive of an atypical antipsychotic activity. Neuropsychopharmacology 28:1889-1902.
22. Dworkin RH, Cornblatt BA (1995). Predicting schizophrenia. Lancet 345: 139-140.
23. Ellenbroek BA, Cools AR (2000). Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11:223-233.
24. Evins AE, Amico E, Posever TA, Toker R, Goff DC (2002). D-Cycloserine added to risperidone in patients with primary negative symptoms of schizophrenia. Schizophr Res 56:19-23.
25. Ghaleiha A, Noorbala AA, Farnaghi F, Hajiazim M, Akhondzadeh S (2010). A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia. J Clin Psychopharmacol 30:678-682.
26. Hamed A, Jaroszewski T, Maciejak P, Szyndler J, Lehner M, Kamecka I, et al. (2009). The effects of buspirone and diazepam on aversive contextand social isolation-induced ultrasonic vocalisation. Physiol Behav 98:474-480.
27. Henry JD, Green MJ, de LA, Restuccia C, McDonald S, ODonnell M (2007). Emotion dysregulation in schizophrenia: reduced amplification of emotional expression is associated with emotional blunting. Schizophr Res 95: 197-204.
28. Hernandez L, Auerbach S, Hoebel BG (1988). Phencyclidine (PCP) injected in the nucleus accumbens increases extracellular dopamine and serotonin as measured by microdialysis. Life Sci 42:1713-1723.
29. Javitt DC (1987). Negative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia. Hillside J Clin Psychiatry 9: 12-35.
30. Javitt DC, Zukin SR (1991). Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
31. Jones SM, Snell LD, Johnson KM (1987a). Inhibition by phencyclidine of excitatory amino acid-stimulated release of neurotransmitter in the nucleus accumbens. Neuropharmacology 26:173-179.
32. Jones SM, Snell LD, Johnson KM (1987b). Phencyclidine selectively inhibits N-methyl-D-aspartate-induced hippocampal [3H]norepinephrine release. J Pharmacol Exp Ther 240:492-497.
33. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771.
34. Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, et al. (1996). Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277:968-981.
35. Kia HK, Miquel MC, Brisorgueil MJ, Daval G, Riad M, El MS, et al. (1996). Immunocytochemical localization of serotonin1A receptors in the rat central nervous system. J Comp Neurol 365:289-305.
36. Knutson B, Burgdorf J, Panksepp J (1998). Anticipation of play elicits highfrequency ultrasonic vocalizations in young rats. J Comp Psychol 112:65-73.
37. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199-214.
38. Lieberman JA (2007). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J Clin Psychiatry 68:e04.
39. Mallo T, Matrov D, Herm L, Koiv K, Eller M, Rinken A, Harro J (2007). Ticklinginduced 50-kHz ultrasonic vocalization is individually stable and predicts behaviour in tests of anxiety and depression in rats. Behav Brain Res 184:57-71.
40. Markou A (2010). Measures of reward responsiveness in animal models of negative symptoms of schizophrenia. Int J Neuropsychopharmacol 13 (Suppl 1):65.
41. McLean SL, Woolley ML, Thomas D, Neill JC (2009). Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology (Berl) 206:403-414.
42. Meltzer HY (1989). Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 99 (Suppl):S18-S27.
43. Meltzer HY, Arvanitis L, Bauer D, ReinW(2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975-984.
44. Nagai T, Murai R, Matsui K, Kamei H, Noda Y, Furukawa H, Nabeshima T (2009). Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 202:315-328.
45. Panksepp J, Beatty WW (1980). Social deprivation and play in rats. Behav Neural Biol 30:197-206.
46. Panksepp J, Burgdorf J (2000). 50-kHz chirping (laughter) in response to conditioned and unconditioned tickle-induced reward in rats: effects of social housing and genetic variables. Behav Brain Res 115:25-38.
47. Panksepp J, Burgdorf J (2003). Laughing rats and the evolutionary antecedents of human joy Physiol Behav 79:533-547.
48. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. (2003). Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 60:681-690.
49. Sams-Dodd F (1995a). Automation of the social interaction test by a videotracking system: behavioural effects of repeated phencyclidine treatment. J Neurosci Methods 59:157-167.
50. Sams-Dodd F (1995b). Distinct effects of D-amphetamine and phencyclidine on the social behaviour of rats. Behav Pharmacol 6:55-65.
51. Schlemmer RF, Davis JM (1983). A comparison of three psychotomimeticinduced models of psychosis in nonhuman primate social colonies. Prog Clin Biol Res 131:33-78.
52. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
53. Snigdha S, Neill JC (2008). Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors. Behav Brain Res 191:26-31.
54. Steinpreis RE, Salamone JD (1993). The role of nucleus accumbens dopamine in the neurochemical and behavioral effects of phencyclidine: A microdialysis and behavioral study. Brain Res 612:263-270.
55. Steinpreis RE, Sokolowski JD, Papanikolaou A, Salamone JD (1994). The effects of haloperidol and clozapine on PCP-and amphetamine-induced suppression of social behavior in the rat. Pharmacol Biochem Behav 47:579-585.
56. Terranova JP, Chabot C, Barnouin MC, Perrault G, Depoortere R, Griebel G, Scatton B (2005). SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit. Psychopharmacology (Berl) 181:134-144.
57. Thompson B, Leonard KC, Brudzynski SM (2006). Amphetamine-induced 50 kHz calls from rat nucleus accumbens: A quantitative mapping study and acoustic analysis. Behav Brain Res 168:64-73.
58. Thomson AM, West DC, Lodge D (1985). An N-methylaspartate receptormediated synapse in rat cerebral cortex: A site of action of ketamine Nature 313:479-481.
59. Tsai GE, Yang P, Chang YC, Chong MY (2006). D-Alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 59:230-234.
60. Umbricht D, Yoo K, Youssef E, Dorflinger E, Martin-Facklam M, Bausch A, et al. (2010). Effects of the glycine transporter Typ1 inhibitor RG1678 in schizophrenic patients with predominant negative symptoms. Neuropsychopharmacology 35 (Suppl 1 (S9)):9-10.
61. Wintink AJ, Brudzynski SM (2001). The related roles of dopamine and glutamate in the initiation of 50-kHz ultrasonic calls in adult rats. Pharmacol Biochem Behav 70:317-323.
62. Yuen EY, Jiang Q, Chen P, Gu Z, Feng J, Yan Z (2005). Serotonin 5-HT1A receptors regulate NMDA receptor channels through a microtubuledependent mechanism. J Neurosci 25:5488-5501.